What is Curi Bio?
Curi Bio operates at the intersection of biotechnology and advanced data analytics, providing an integrated platform that combines 3D tissue models with automated biosystems. The company's core value proposition lies in its ability to generate highly predictive human data, which is essential for assessing drug safety, efficacy, and potency before human testing. By bridging the gap between preclinical research and clinical outcomes, Curi Bio enables biopharmaceutical companies to make more informed, data-driven decisions, ultimately reducing the high failure rates associated with drug development. Their market position is defined by a commitment to innovation in human stem cell technology, serving as a critical partner for global pharmaceutical end users seeking to optimize their R&D workflows.
How much funding has Curi Bio raised?
Curi Bio has raised a total of $26.1M across 3 funding rounds:
Debt
$150K
Series A
$16M
Series B
$10M
Debt (2020): $150K with participation from PPP
Series A (2021): $16M led by DS Asset Management, DYNAMK CAPITAL, and UTC Investment
Series B (2025): $10M supported by DreamCIS
Key Investors in Curi Bio
DS Asset Management
A South Korean investment management firm focused on deep industry insights and long-term asset growth through public and private fund management.
DYNAMK CAPITAL
A venture capital firm specializing in growth-stage investments within the life sciences and bioprocessing sectors.
DreamCIS
A clinical development service provider offering comprehensive solutions for clinical trials across various therapeutic areas including oncology and rare diseases.
What's next for Curi Bio?
With the recent infusion of capital, Curi Bio is expected to accelerate the commercialization of its advanced 3D tissue models and expand its automated data analysis capabilities. The strategic focus will likely center on deepening partnerships with major pharmaceutical entities and enhancing the throughput of its preclinical platforms. As the company matures, the integration of its technology into standard drug discovery protocols will be a key performance indicator. Furthermore, the firm is poised to capitalize on the increasing regulatory and industry pressure for more accurate, human-relevant preclinical data, positioning itself as an indispensable asset in the global effort to bring safer, more effective medicines to market faster.
See full Curi Bio company page
